The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
“Immunotherapy-alone [patients] had similar rates of death compared with those not on treatment within the past year,” Dr Wise-Draper emphasized.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
Engineered cytokine evades the tumor’s defenses and boosts the production of stem-like polyfunctional T cells.
Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.
Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.
Patients with cancer and COVID-19 had high rates of hospitalization and/or respiratory illness, particularly among those taking immunotherapy or those older than 65 years.
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
A review of practices prior to a change in nivolumab dosing demonstrated that bodyweight dosing resulted in a 6.1% rate of wastage at a significant cost compared with a fixed dose of 240 mg per dose.
